On this page
Back to topAvalyn Pharma AVLN
Avalyn Pharma listed on Nasdaq on 30 Apr 2026 and is not in the S&P 500. It is worth $1.3 billion. Its price history starts on 1 May 2026. 8 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 4 other officers are on file. At 30 Jun 2026, Fidelity (FMR) was its largest institutional holder, with 13.2% of the company.
- CEO
- Lyn Baranowski
- Listed
- 30 Apr 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Boston, MA
- Market cap
- $1.3B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Avalyn Pharma's market cap since May 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.4B |
Download Avalyn Pharma's data as JSON, with the weekly market caps in billions of dollars from 1 May 2026.
Board and leadership
Board and officers
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (8) | |
| Lyn BaranowskiChief Executive Officer | |
| Jill CarrollDirector | |
| Jon CongletonDirector | |
| David Matthew FriedmanDirector | |
| Kate HavilandDirector | |
| Erin LavelleDirector | |
| Robert J. MeyerDirector | |
| Heather D. TurnerDirector | |
| Officers (4) | |
| Douglas R. CarlsonChief Financial OfficerLast filed 1 May 2026 | |
| Adam H. GoldenGeneral CounselLast filed 4 May 2026 | |
| Howard LazarusChief Medical OfficerLast filed 1 May 2026 | |
| Melissa RhodesChief Operating OfficerLast filed 1 May 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of Avalyn Pharma. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $2.6 million of stock in 5 sales and bought $5.0 million in 1 purchase in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 18 Nov 2026Sale | Lyn BaranowskiChief Executive Officer | $201K |
| 17 Nov 2026Sale | Lyn BaranowskiChief Executive Officer | $1.3M |
| 17 Nov 2026Sale | Douglas R. CarlsonChief Financial Officer | $415K |
| 17 Nov 2026Sale | Melissa RhodesChief Operating Officer | $371K |
| 17 Nov 2026Sale | Howard LazarusChief Medical Officer | $371K |
| 1 May 2026Buy | Jill CarrollDirector | $5.0M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
0 departures and 1 appointment of directors and officers and 1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Avalyn Pharma's insider sales.
Events, newest first
- 17 Nov 2026 Lyn Baranowski sold $1.3MChief Executive Officer
- 15 Sep 2026 Robert Meyer appointedClass II director
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.